| GANX |
Gain Therapeutics, Inc. |
72%
|
Reciprocal relationship from GANX graph: Reciprocal relationship from ALEC graph: t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to furt… |
| GANX |
Gain Therapeutics, Inc. |
72%
|
t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to further develop our current product candidates. For example, clinical trials of our pr… |
| HTGC |
Hercules Capital, Inc. |
72%
|
h pipeline. We initiated that reduction in force impacting approximately 25 employees across the organization. On October 21, 2025, we committed to a plan to reduce our workforce by approximately 47%… |
| HTGC |
Hercules Capital, Inc. |
72%
|
Reciprocal relationship from HTGC graph: Reciprocal relationship from ALEC graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ALEC graph: h pipeline. We initiated that reduc… |
| LLY |
Eli Lilly and Company |
72%
|
t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to further develop our current product candidates. For example, clinical trials of our pr… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from ALEC graph: t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to furth… |
| VYGR |
Voyager Therapeutics, Inc. |
72%
|
t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to further develop our current product candidates. For example, clinical trials of our pr… |
| VYGR |
Voyager Therapeutics, Inc. |
72%
|
Reciprocal relationship from VYGR graph: Reciprocal relationship from ALEC graph: t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to furt… |
| ABBVIE-BIOTECHNOLOGY-LTD |
ABBVIE-BIOTECHNOLOGY-LTD |
62%
|
pects. • Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates. Risks Relat… |
| COMPANY-LLC |
COMPANY-LLC |
62%
|
h pipeline. We initiated that reduction in force impacting approximately 25 employees across the organization. On October 21, 2025, we committed to a plan to reduce our workforce by approximately 47%… |
| DENALI-THERAPEUTICS-INC |
DENALI-THERAPEUTICS-INC |
62%
|
t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to further develop our current product candidates. For example, clinical trials of our pr… |
| DNLI |
Denali Therapeutics Inc. |
62%
|
Reciprocal relationship from DNLI graph: Reciprocal relationship from ALEC graph: t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to furt… |
| EISAI-CO-LTD |
EISAI-CO-LTD |
62%
|
t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to further develop our current product candidates. For example, clinical trials of our pr… |
| USA-LLC |
USA-LLC |
62%
|
nd increase our costs and expenses. Our operations, and those of our collaborators, CROs, CDMOs, suppliers, and other contractors and consultants, could be subject to events beyond our control, such … |
